Enabling patients with autoimmune diseases to reimagine life. Backed by NEA and Norwest.
About the role
The Associate Director, Medical Science Liaisons (MSLs), Neurology, at Zenas are the field-based extension of our Medical Affairs department. MSLs are scientifically-trained professionals who possess strong clinical and/or scientific backgrounds whose role is to be a resource of fair-balanced and scientifically-rigorous information to the healthcare community. This position reports to the Director, MSLs, Neurology.
What they're looking for
- Advanced clinical/science degree or health care professional credentials required (MD, PhD, RPh, PharmD, NP, PA, MS or equivalent)
- Minimum 3+ years MSL, field-based, or clinical position preferred
- Therapeutic area experience preferred
- Knowledge of treatment guidelines, clinical research processes, FDA regulations, and Officer of Inspector General (OIG) guidelines preferred
- Outstanding interpersonal skills, including building strong working relationships and managing and resolving conflict
- Excellent communication skills (written, verbal, listening, and presentation)
More about this role
Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab’s unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively address the pathogenic role of B cell lineage in chronic autoimmune disease. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule Bruton’s Tyrosine Kinase...
Browse similar: Startup jobs